Fig. 6

CXCR4 inhibitors restore palbociclib sensitivity in palbociclib-resistant breast cancer in vivo. MCF7-palR cells were inoculated into the mammary fat pads of BALB/c mice. When tumors became palpable, mice were administrated with palbociclib (100 mg/kg, once a day) by gavage or AMD3100 (5 mg/kg, every 3 days) by intraperitoneal injection. a Tumor picture at the left panel and growth curve at the right panel. b IHC staining showing the expression of CXCR4, WNT5A, β-catenin and ki67. Representative images of IHC staining at the top panel and statistical analysis at the bottom panel. n = 6 mice per group, means ± s.d. were shown, and p values were determined by one-way ANOVAs, ***p < 0.001 and ns for p > 0.05. Scale bars represent 50 μm